XERS Stock Analysis: Buy, Sell, or Hold?
XERS - Xeris Biopharma Holdings, Inc. Common Stock
$8.28
0.28 (3.50%)
▲
5d:
+11.89%
30d:
+38.0%
90d:
+37.09%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Distribution
None View Scanner →
Strength: 4.0/10
Get Alerted When XERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: XERS is 10.4% above its trading range ($7.50). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: XERS is 10.4% above its trading range ($7.50). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.38
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$8.93
7.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XERS is currently trading at $8.28, which is considered extended relative to its 30-day fair value range of $6.17 to $7.50. From a valuation perspective, the stock is trading at a premium (Forward PE: 21.0) compared to its historical average (18.7). At these levels, the market is pricing in 3.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XERS is in a uptrend. The price is approaching resistance at $8.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: XERS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.29 (+36.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, XERS is in a uptrend. The price is approaching resistance at $8.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: XERS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.29 (+36.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.17 -
$7.50
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
All Signals
- BEARISH: Price significantly overextended (+10.4% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 36.3% below Wall St target ($11.29)
- NEUTRAL: Market pricing in 3.8% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$6.17 -
$7.50
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.86
Resistance Level
$8.38
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.96
Wall Street Target
$11.29
(+36.3%)
Revenue Growth (YoY)
38.3%
Profit Margin
3.8%
Valuation Premium vs History
+3.8% premium
PE vs Historical
21.0 vs 18.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.8%
(market-implied from PE analysis)
1-Year Target
$8.59
(+4%)
2-Year Target
$8.92
(+8%)
3-Year Target
$9.26
(+12%)
3-Yr Target (if PE normalizes)
(PE: 21→19)
PE COMPRESSION
$8.26
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 177.2%)
$29.04
(+251%)
Base:
(SPY PE: 21.0, Growth: 177.2%)
$27.95
(+238%)
Bear:
(PE: 17.8, Growth: 177.2%)
$23.75
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (100x PE), but valuation improves significantly next year (21x PE) as earnings recover.
Forward PE: 100.00 | Forward EPS (Implied): $0.08
Bull Case
$10.00
(+21%)
Analyst growth 15.0%, PE expands to 105.0
Base Case
$8.28
(0%)
Market implied 0.0%, PE stable at 100.0
Bear Case
$6.33
(-24%)
Severe decline -15.0%, PE contracts to 90.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 5:06 PM ET
Data refreshes hourly during market hours. Next update: 6:06 PM
Data refreshes hourly during market hours. Next update: 6:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Beth Hecht
SELL
16667 shares
2026-04-01
James Aloysius Brady
SELL
10834 shares
2026-03-30
Beth Hecht
SELL
16667 shares
2026-03-02
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 63 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 54 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 60 HOLD |